Crane Company delivered a strong finish to 2025 with Q4 adjusted EPS of $1.53, up 21% year-over-year, driven by a 5.4% increase in core sales. Full-year adjusted EPS rose 24%, supported by robust performance in the Aerospace & Advanced Technologies (AAT) segment, which saw sales grow 15% organically, and margin expansion in Process Flow Technologies (PFT) despite flat sales. The company successfully closed four acquisitions (Druck, Panametrics, Reuter-Stokes, and optek-Danulat), positioning it for accelerated growth and expanding its nuclear and instrumentation capabilities. Management initiated 2026 guidance for adjusted EPS of $6.55 to $6.75, representing roughly 10% growth at the midpoint, with core sales growth expected between 4% and 6%. Additionally, the company announced a leadership transition, with Alex Alcala set to become CEO in April 2026, while Max Mitchell will move to Executive Chairman.
| Metric | Value | Change |
|---|---|---|
| Q4 Adjusted EPS | $1.53 | +21% YoY |
| Q4 Core Sales Growth | 5.4% | N/A |
| FY 2025 Adjusted EPS Growth | 24% | N/A |
| AAT Q4 Sales | $272 million | +15% YoY |
| PFT Q4 Sales | $309 million | Flat YoY |
| Net Leverage (Post-optek) | 1.4x | N/A |
| 2026 Adjusted EPS Guidance | $6.55 - $6.75 | +10% at midpoint |
| 2026 Core Sales Growth Guidance | 4% - 6% | N/A |
M&A Integration and Synergy Capture: Crane closed the acquisition of the Baker Hughes Instrumentation businesses (Druck, Panametrics, Reuter-Stokes) and optek-Danulat. Management is already exceeding initial integration expectations, moving the 2026 accretion outlook from 'neutral' to 'slightly accretive.' The Crane Business System (CBS) is being deployed to drive cost synergies through organizational simplification (eliminating the PSI headquarters layer) and product line rationalization (80/20 rule). This signals a disciplined approach to inorganic growth that immediately enhances the earnings profile.
Segment Transformation and Rebranding: The renaming of the 'Aerospace & Electronics' segment to 'Aerospace & Advanced Technologies' signals a strategic widening of the aperture. The addition of Druck allows Crane to expand into ground-based test equipment and industrial applications beyond traditional aerospace. This reflects a strategy to leverage proprietary, differentiated technologies into adjacent high-growth markets while maintaining sole-source positions in core aerospace programs.
Resilience in Process Flow Technologies (PFT): Despite a 'trough' environment in chemical markets, PFT maintained a 22% adjusted operating margin (up 170 bps) through pricing and productivity. The portfolio shift towards higher-growth verticals like pharmaceuticals (specifically GLP-1 capacity expansion), cryogenics (space launch), and water treatment is mitigating macro weakness. The acquisition of optek-Danulat further strengthens the biopharma and pharma instrumentation offering, aligning with the strategy to move up the technology stack.
Nuclear Energy Tailwinds: The acquisition of Reuter-Stokes doubles Crane's exposure to the nuclear market. Management identified four specific growth drivers: plant restarts (e.g., Three Mile Island), new construction (AP1000), Small Modular Reactors (SMRs), and life extensions (license renewals). This positions Crane as a key beneficiary of the renewed global interest in nuclear power as a baseload clean energy source.
Leadership Succession and Continuity: The appointment of Alex Alcala to CEO, with Max Mitchell transitioning to Executive Chairman, ensures strategic continuity. Alcala, a 13-year veteran, has been instrumental in the portfolio transformation and margin improvement. The smooth transition plan, coupled with Alcala's deep operational expertise, suggests the strategic priorities (M&A, CBS execution, margin expansion) will remain unchanged, reducing key person risk.
PFT Chemical Market Weakness: Management acknowledged that chemical end markets remain at 'trough levels' with no immediate recovery expected in 2026. Core FX-neutral orders in PFT were down 3% in Q4, and backlog decreased 7%. The guidance for PFT core growth in 2026 is conservative ('flat to low single digit'), indicating that a significant portion of the portfolio remains under pressure from broader industrial macroeconomic headwinds.
Near-Term Margin Dilution: While the recent acquisitions are expected to be accretive to EPS in 2026, management explicitly stated that Druck and the PSI businesses (Panametrics, Reuter-Stokes) will be 'dilutive to overall segment margin in the near term.' This creates a dynamic where earnings growth is driven by accretion and corporate expense leverage, but segment margins may face headwinds from integration costs and the lower margin profile of the new businesses initially.
Q1 2026 Seasonality and Softness: Management warned that Q1 2026 will be the 'seasonally softest quarter' and is expected to come in roughly flat with Q1 2025. This softness is attributed to acquisition integration costs, increased interest expense, and the seasonality of the acquired businesses (which are stronger in H2). This sets up a difficult year-over-year comparison for the first half of the year.
F-16 Program Delays: A specific near-term operational hiccup involves the F-16 brake control program. Flight testing was delayed a few months due to the government shutdown, pushing the completion of the test into early Q2 2026. While the orders are in backlog, this delays revenue recognition and creates a timing headwind for the first half of the year.
Balance Sheet Leverage: Following the recent acquisitions, net leverage has risen to 1.4x. While management stated they are comfortable going up to 3.0x for the right deal, the increased debt load results in higher interest expenses (~$58 million estimated for 2026) which acts as a drag on earnings growth in the near term.
Overall: Management exhibited a high level of confidence and enthusiasm throughout the call, emphasizing the strength of the team's execution and the strategic value of recent acquisitions. The tone was celebratory regarding the 2025 results and the CEO succession, yet remained disciplined and specific regarding 2026 guidance and integration plans. There was a notable focus on 'momentum' and 'reliability' in delivering shareholder value.
Confidence: HIGH - Management provided specific guidance ranges, detailed synergy targets for recent acquisitions, and articulated a clear strategic roadmap. The willingness to leverage the balance sheet for further M&A and the early outperformance of acquisition integration signals strong internal conviction.
$6.55 to $6.75 (approx. 10% growth at midpoint excluding 2025 insurance recoveries)
4% to 6%
35% to 40%
Approximately $58 million
Approximately 23%
Expected to be roughly flat with Q1 2025
Hedging & Uncertainty: Management generally used direct and confident language regarding execution and long-term strategy ('consistently and reliably delivering,' 'highly confident'). However, hedging was more prevalent when discussing the macro environment for PFT. Phrases like 'cautious view of 2026 demand levels,' 'not planning for a strong uptick,' and 'trough levels' were used to set conservative expectations for the chemical markets. There was also temporal hedging regarding the accretion of acquisitions, noting they are accretive in 2026 but 'dilutive to overall segment margin in the near term,' which manages investor expectations regarding immediate profitability.
Consistently and reliably delivering on our commitments and our long-term value creation thesis. - Max Mitchell, Chairman, President and CEO
We're always working to over-deliver. - Max Mitchell, Chairman, President and CEO
We are adopting a cautious view of 2026 demand levels to start the year. - Alejandro Alcala, COO and incoming CEO
The integration process is off to a strong start, and our outlook for these businesses is already exceeding our initial expectations. - Alejandro Alcala, COO and incoming CEO
We expect to selectively and carefully widen our aperture in this segment without losing focus on what differentiates us. - Max Mitchell, Chairman, President and CEO
We see many opportunities progressing through 2026, but at this time, nothing additional is imminent in Q1. - Max Mitchell, Chairman, President and CEO
Analyst Sentiment: Analysts were largely congratulatory regarding the leadership transition and the strong 2025 performance. Questions focused heavily on the mechanics of the recent acquisitions (synergies, integration costs, margin accretion) and the specific demand outlook for the Chemical and Aerospace end markets.
Management Responses: Management was detailed and transparent in their responses, providing specific color on the timing of synergies (noting 202bps margin improvement in year 1 for PSI) and the regional variances in chemical demand. They effectively deflected concerns about balance sheet capacity by stating a willingness to go to 3.0x leverage for the right deal.
Pricing and LTAs for Druck acquisition: Management confirmed significant opportunities for value pricing and contract renewals, with improvements expected to start this year and read through more heavily into 2027.
PFT Chemical Market Outlook: Management clarified that while Americas and Middle East are seeing growth, Europe and Asia Pac remain weak. They are not planning for a strong uptick in 2026 but are ready to capture it if it occurs.
Integration Costs vs. Run-rate Costs: CFO Rich Maue clarified that direct integration costs will be excluded from adjusted results, but investments to build capabilities (e.g., hiring in finance/IT) will remain in the reported numbers.
F-16 Program Impact: Management clarified that while flight testing delays pushed some revenue into Q2, the annual rate of ~$30M remains intact, and foreign military sales will extend the program tail.
Crane Company is executing a highly effective 'build and buy' strategy that is reshaping its portfolio towards higher-growth, higher-margin proprietary technologies. The 2025 results demonstrated strong operational leverage and resilience, particularly in the Aerospace segment, which boasts a record $1B+ backlog. The recent acquisitions (Druck, Panametrics, Reuter-Stokes, optek) not only enhance the company's exposure to secular growth trends like Nuclear, Pharma, and Aerospace sensing but are already performing ahead of plan. The leadership transition to Alex Alcala appears seamless, ensuring the continuation of the successful 'Crane Business System' culture. While near-term headwinds exist in PFT chemicals and Q1 seasonality, the 10% EPS growth guidance for 2026 appears conservative given the early accretion from deals and the robust backlog. The company's disciplined capital allocation and ability to integrate carve-outs successfully support a positive investment thesis.
Commercial OEM production is ramping up (Boeing/Airbus), and defense procurement remains solid. Management noted 'elevated interest' in air defense systems and high-power AESA radar opportunities.
Chemical end markets are described as being at 'trough levels' with sluggish demand, particularly in Europe, China, and the rest of Asia Pac. No strong recovery is expected in 2026 guidance.
Management identified a 'pretty attractive' growth environment driven by plant restarts (e.g., Three Mile Island), new construction (AP1000), Small Modular Reactors (SMRs), and license extensions.
Strong demand driven by capacity expansion for GLP-1 drugs and reshoring efforts in North America.